Genotypic and Clinical Heterogeneity Amongst NCCN Favorable-Risk Acute Myeloid Leukemias

被引：0
|
作者：
Seegmiller, Adam
Strickland, Stephen A.
Shaver, Aaron C.
Daber, Robert D.
Byrne, Michael
Ferrell, P. B.
Head, David R.
Mohan, Sanjay R.
Vnencak-Jones, Cindy L.
Zutter, Maly M.
Savona, Michael R.
机构：
[1] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[2] BioReference Labs, Elmwood Pk, NJ USA
来源：
MODERN PATHOLOGY | 2017年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1504
引用
收藏
页码：375A / 375A
页数：1
相关论文
共 50 条
  • [1] Genotypic and Clinical Heterogeneity Amongst NCCN Favorable-Risk Acute Myeloid Leukemias
    Seegmiller, Adam
    Strickland, Stephen A.
    Shaver, Aaron C.
    Daber, Robert D.
    Byrne, Michael
    Ferrell, P. B.
    Head, David R.
    Mohan, Sanjay R.
    Vnencak-Jones, Cindy L.
    Zutter, Mary M.
    Savona, Michael R.
    LABORATORY INVESTIGATION, 2017, 97 : 375A - 375A
  • [2] Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia
    Strickland, Stephen A.
    Shaver, Aaron C.
    Byrne, Michael
    Daber, Robert D.
    Ferrell, P. Brent
    Head, David R.
    Mohan, Sanjay R.
    Mosse, Claudio A.
    Moyo, Tamara K.
    Stricker, Thomas P.
    Vnencak-Jones, Cindy
    Savona, Michael R.
    Seegmiller, Adam C.
    LEUKEMIA RESEARCH, 2018, 65 : 67 - 73
  • [3] Clinical and biological features of favorable-risk acute myelogenous leukemia – is favorable-risk AML really favorable?
    G J Schiller
    Leukemia, 2005, 19 : 326 - 328
  • [4] Clinical and biological features of favorable-risk acute myelogenous leukemia - is favorable-risk AML really favorable?
    Schiller, GJ
    LEUKEMIA, 2005, 19 (03) : 326 - 328
  • [5] Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna
    Naidoo, Nuthana
    Lombardi, Jennifer
    Pullarkat, Vinod
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : E59 - E63
  • [6] Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna A.
    Naidoo, Nuthana
    Story, Jennifer Lombardi
    Pullarkat, Vinod A.
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    BLOOD, 2020, 136
  • [7] Acute myeloid leukemia including favorable-risk group samples engraft in NSG mice: just be patient
    Bonnet, Dominique
    HAEMATOLOGICA, 2017, 102 (05) : 805 - 806
  • [8] Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
    Chen, Juan
    Liu, Li
    Ma, Runzhi
    Pang, Aiming
    Yang, Donglin
    Chen, Xin
    Wei, Jialin
    He, Yi
    Zhang, Rongli
    Zhai, Weihua
    Ma, Qiaoling
    Jiang, Erlie
    Han, Mingzhe
    Zhou, Jiaxi
    Feng, Sizhou
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [9] Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
    Juan Chen
    Li Liu
    Runzhi Ma
    Aiming Pang
    Donglin Yang
    Xin Chen
    Jialin Wei
    Yi He
    Rongli Zhang
    Weihua Zhai
    Qiaoling Ma
    Erlie Jiang
    Mingzhe Han
    Jiaxi Zhou
    Sizhou Feng
    Cancer Cell International, 22
  • [10] Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia
    Jiang, Hao
    Liu, Xiao-Hong
    Kong, Jun
    Wang, Jing
    Jia, Jin-Song
    Lu, Sheng-Ye
    Gong, Li-Zhong
    Zhao, Xiao-Su
    Jiang, Qian
    Chang, Ying-Jun
    Wang, Yu
    Ruan, Guo-Rui
    Qin, Ya-Zhen
    Liu, Kai-Yan
    Huang, Xiao-Jun
    LEUKEMIA & LYMPHOMA, 2021, 62 (12) : 2949 - 2956
12345